{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:45:20Z","timestamp":1785804320363,"version":"3.56.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"STI2030-Major Projects","award":["2022ZD0211606"],"award-info":[{"award-number":["2022ZD0211606"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82021002, 82272039, and 82394434"],"award-info":[{"award-number":["82021002, 82272039, and 82394434"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-026-02098-1","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T06:42:48Z","timestamp":1780123368000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["White matter 18F-florbetapir retention predicts cognitive decline and treatment response in Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"18","author":[{"given":"Huamei","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqing","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwei","family":"Men","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjie","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongguang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Chen","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junlong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuangyu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Rominger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihui","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jintai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiehui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuantao","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"issue":"6","key":"2098_CR1","doi-asserted-by":"publisher","first-page":"e2513931","DOI":"10.1001\/jamanetworkopen.2025.13931","volume":"8","author":"S Mudrazija","year":"2025","unstructured":"Mudrazija S, et al. Economic burden of Alzheimer disease and related dementias by race and ethnicity, 2020 to 2060. JAMA Netw Open. 2025;8(6):e2513931.","journal-title":"JAMA Netw Open"},{"issue":"8","key":"2098_CR2","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack CR Jr., et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. 2024;20(8):5143\u201369.","journal-title":"Alzheimers Dement"},{"issue":"8","key":"2098_CR3","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324(8):772\u201381.","journal-title":"JAMA"},{"issue":"4","key":"2098_CR4","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1007\/s00259-021-05493-y","volume":"49","author":"A Moscoso","year":"2022","unstructured":"Moscoso A, et al. (18)F-florbetapir PET as a marker of myelin integrity across the Alzheimer\u2019s disease spectrum. Eur J Nucl Med Mol Imaging. 2022;49(4):1242\u201353.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"2098_CR5","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1007\/s00259-021-05195-5","volume":"48","author":"A Moscoso","year":"2021","unstructured":"Moscoso A, et al. Reduced [(18)F]flortaucipir retention in white matter hyperintensities compared to normal-appearing white matter. Eur J Nucl Med Mol Imaging. 2021;48(7):2283\u201394.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7964","key":"2098_CR6","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41586-023-06120-6","volume":"618","author":"C Depp","year":"2023","unstructured":"Depp C, et al. Myelin dysfunction drives amyloid-beta deposition in models of Alzheimer\u2019s disease. Nature. 2023;618(7964):349\u201357.","journal-title":"Nature"},{"issue":"4","key":"2098_CR7","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1093\/brain\/awac436","volume":"146","author":"CWJ van der Weijden","year":"2023","unstructured":"van der Weijden CWJ, et al. Quantitative myelin imaging with MRI and PET: an overview of techniques and their validation status. Brain. 2023;146(4):1243\u201366.","journal-title":"Brain"},{"key":"2098_CR8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s40478-014-0083-0","volume":"2","author":"LE Collins-Praino","year":"2014","unstructured":"Collins-Praino LE, et al. Soluble amyloid beta levels are elevated in the white matter of Alzheimer\u2019s patients, independent of cortical plaque severity. Acta Neuropathol Commun. 2014;2:83.","journal-title":"Acta Neuropathol Commun"},{"issue":"12","key":"2098_CR9","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1016\/j.neurobiolaging.2012.01.016","volume":"33","author":"T Grimmer","year":"2012","unstructured":"Grimmer T, et al. White matter hyperintensities predict amyloid increase in Alzheimer\u2019s disease. Neurobiol Aging. 2012;33(12):2766\u201373.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"2098_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13195-020-00759-3","volume":"13","author":"M Gaubert","year":"2021","unstructured":"Gaubert M, et al. Topographic patterns of white matter hyperintensities are associated with multimodal neuroimaging biomarkers of Alzheimer\u2019s disease. Alzheimers Res Ther. 2021;13(1):29.","journal-title":"Alzheimers Res Ther"},{"issue":"7","key":"2098_CR11","doi-asserted-by":"publisher","first-page":"4916","DOI":"10.1007\/s12035-018-1405-1","volume":"56","author":"LP Schilling","year":"2019","unstructured":"Schilling LP, et al. Regional amyloid-beta load and white matter abnormalities contribute to hypometabolism in Alzheimer\u2019s dementia. Mol Neurobiol. 2019;56(7):4916\u201324.","journal-title":"Mol Neurobiol"},{"issue":"4","key":"2098_CR12","doi-asserted-by":"publisher","first-page":"e313","DOI":"10.1212\/WNL.0000000000005864","volume":"91","author":"JF Strain","year":"2018","unstructured":"Strain JF, et al. Loss of white matter integrity reflects tau accumulation in Alzheimer disease defined regions. Neurology. 2018;91(4):e313\u20138.","journal-title":"Neurology"},{"issue":"12","key":"2098_CR13","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1016\/j.jalz.2015.05.014","volume":"11","author":"G Tosto","year":"2015","unstructured":"Tosto G, et al. The effect of white matter hyperintensities on neurodegeneration in mild cognitive impairment. Alzheimers Dement. 2015;11(12):1510\u20139.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"2098_CR14","doi-asserted-by":"publisher","first-page":"3931","DOI":"10.1002\/alz.13845","volume":"20","author":"J Zhang","year":"2024","unstructured":"Zhang J, et al. Linking white matter hyperintensities to regional cortical thinning, amyloid deposition, and synaptic density loss in Alzheimer\u2019s disease. Alzheimers Dement. 2024;20(6):3931\u201342.","journal-title":"Alzheimers Dement"},{"issue":"Suppl 9","key":"2098_CR15","first-page":"S89","volume":"19","author":"A Eloyan","year":"2023","unstructured":"Eloyan A, et al. White matter hyperintensities are higher among early-onset Alzheimer\u2019s disease participants than their cognitively normal and early-onset nonAD peers: Longitudinal Early-onset Alzheimer\u2019s Disease Study (LEADS). Alzheimers Dement. 2023;19(Suppl 9):S89\u201397.","journal-title":"Alzheimers Dement"},{"issue":"14","key":"2098_CR16","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1016\/j.neuron.2021.05.012","volume":"109","author":"JF Chen","year":"2021","unstructured":"Chen JF, et al. Enhancing myelin renewal reverses cognitive dysfunction in a murine model of Alzheimer\u2019s disease. Neuron. 2021;109(14):2292\u2013e23075.","journal-title":"Neuron"},{"issue":"1","key":"2098_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.neurobiolaging.2014.07.019","volume":"36","author":"AM Brickman","year":"2015","unstructured":"Brickman AM, et al. Reconsidering harbingers of dementia: progression of parietal lobe white matter hyperintensities predicts Alzheimer\u2019s disease incidence. Neurobiol Aging. 2015;36(1):27\u201332.","journal-title":"Neurobiol Aging"},{"key":"2098_CR18","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.nicl.2015.09.009","volume":"9","author":"AE Goodheart","year":"2015","unstructured":"Goodheart AE, et al. Reduced binding of Pittsburgh Compound-B in areas of white matter hyperintensities. Neuroimage Clin. 2015;9:479\u201383.","journal-title":"Neuroimage Clin"},{"issue":"1","key":"2098_CR19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00259-014-2897-1","volume":"42","author":"L Glodzik","year":"2015","unstructured":"Glodzik L, et al. Reduced retention of Pittsburgh compound B in white matter lesions. Eur J Nucl Med Mol Imaging. 2015;42(1):97\u2013102.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2098_CR20","first-page":"p","volume":"102138","author":"P Sun","year":"2025","unstructured":"Sun P, et al. White matter fractional anisotropy decreases precede hyperintensities in Alzheimer\u2019s disease. Cell Rep Med. 2025;102138:p.","journal-title":"Cell Rep Med"},{"issue":"5","key":"2098_CR21","first-page":"904","volume":"39","author":"OG Rousset","year":"1998","unstructured":"Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: principle and validation. J Nucl Med. 1998;39(5):904\u201311.","journal-title":"J Nucl Med"},{"issue":"1","key":"2098_CR22","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13195-021-00836-1","volume":"13","author":"SK Royse","year":"2021","unstructured":"Royse SK, et al. Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach. Alzheimers Res Ther. 2021;13(1):99.","journal-title":"Alzheimers Res Ther"},{"issue":"5","key":"2098_CR23","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.jalz.2015.09.009","volume":"12","author":"T Bittner","year":"2016","unstructured":"Bittner T, et al. Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of beta-amyloid (1\u201342) in human cerebrospinal fluid. Alzheimers Dement. 2016;12(5):517\u201326.","journal-title":"Alzheimers Dement"},{"issue":"5","key":"2098_CR24","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41582-024-00955-x","volume":"20","author":"M Khalil","year":"2024","unstructured":"Khalil M, et al. Neurofilaments as biomarkers in neurological disorders - towards clinical application. Nat Rev Neurol. 2024;20(5):269\u201387.","journal-title":"Nat Rev Neurol"},{"key":"2098_CR25","doi-asserted-by":"crossref","unstructured":"Maschio CA, et al. Increased levels of GFAP and purinergic P2X7 receptor in Alzheimer\u2019s disease brain are associated with A\u03b2, tau pathologies and synaptic loss. Alzheimer\u2019s Research & Therapy. 2025;17(1):274.","DOI":"10.1186\/s13195-025-01916-2"},{"issue":"1","key":"2098_CR26","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40035-025-00508-2","volume":"14","author":"J Nussbaumer","year":"2025","unstructured":"Nussbaumer J, et al. Reduced synaptic vesicle protein 2A in extracellular vesicles and brains of Alzheimer\u2019s disease: associations with abeta, tau, synaptic proteins and APOE epsilon4. Transl Neurodegener. 2025;14(1):48.","journal-title":"Transl Neurodegener"},{"issue":"4","key":"2098_CR27","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine ZS, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695\u20139.","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"2098_CR28","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/ana.23908","volume":"74","author":"SM Landau","year":"2013","unstructured":"Landau SM, et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of beta-amyloid. Ann Neurol. 2013;74(6):826\u201336.","journal-title":"Ann Neurol"},{"issue":"2","key":"2098_CR29","doi-asserted-by":"publisher","first-page":"198","DOI":"10.2967\/jnumed.108.057984","volume":"50","author":"MT Fodero-Tavoletti","year":"2009","unstructured":"Fodero-Tavoletti MT, et al. Characterization of PiB binding to white matter in Alzheimer disease and other dementias. J Nucl Med. 2009;50(2):198\u2013204.","journal-title":"J Nucl Med"},{"issue":"1","key":"2098_CR30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13195-024-01407-w","volume":"16","author":"H Hong","year":"2024","unstructured":"Hong H, et al. The relationship between amyloid pathology, cerebral small vessel disease, glymphatic dysfunction, and cognition: a study based on Alzheimer\u2019s disease continuum participants. Alzheimers Res Ther. 2024;16(1):43.","journal-title":"Alzheimers Res Ther"},{"issue":"6","key":"2098_CR31","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1093\/brain\/awy086","volume":"141","author":"R Mito","year":"2018","unstructured":"Mito R, et al. Reply: Cortical tau pathology: a major player in fibre-specific white matter reductions in Alzheimer\u2019s disease? Brain. 2018;141(6):e45.","journal-title":"Brain"},{"issue":"3","key":"2098_CR32","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1093\/brain\/awx355","volume":"141","author":"R Mito","year":"2018","unstructured":"Mito R, et al. Fibre-specific white matter reductions in Alzheimer\u2019s disease and mild cognitive impairment. Brain. 2018;141(3):888\u2013902.","journal-title":"Brain"},{"issue":"5","key":"2098_CR33","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1002\/hbm.24877","volume":"41","author":"A Brugulat-Serrat","year":"2020","unstructured":"Brugulat-Serrat A, et al. White matter hyperintensities mediate gray matter volume and processing speed relationship in cognitively unimpaired participants. Hum Brain Mapp. 2020;41(5):1309\u201322.","journal-title":"Hum Brain Mapp"},{"key":"2098_CR34","doi-asserted-by":"crossref","unstructured":"Cai Y et al. Myelin-axon interface vulnerability in Alzheimer\u2019s disease revealed by subcellular proteomics and imaging of human and mouse brain. Nat Neurosci. 2025;28(7):1418\u201335.","DOI":"10.1038\/s41593-025-01973-8"},{"issue":"4","key":"2098_CR35","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1093\/brain\/awx003","volume":"140","author":"G Banerjee","year":"2017","unstructured":"Banerjee G, et al. MRI-visible perivascular space location is associated with Alzheimer\u2019s disease independently of amyloid burden. Brain. 2017;140(4):1107\u201316.","journal-title":"Brain"},{"issue":"3","key":"2098_CR36","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s00401-021-02393-1","volume":"143","author":"V Perosa","year":"2022","unstructured":"Perosa V, et al. Perivascular space dilation is associated with vascular amyloid-beta accumulation in the overlying cortex. Acta Neuropathol. 2022;143(3):331\u201348.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"2098_CR37","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40478-018-0515-3","volume":"6","author":"SE Nasrabady","year":"2018","unstructured":"Nasrabady SE, et al. White matter changes in Alzheimer\u2019s disease: a focus on myelin and oligodendrocytes. Acta Neuropathol Commun. 2018;6(1):22.","journal-title":"Acta Neuropathol Commun"},{"issue":"4","key":"2098_CR38","doi-asserted-by":"publisher","first-page":"560","DOI":"10.2967\/jnumed.114.149732","volume":"56","author":"K Chen","year":"2015","unstructured":"Chen K, et al. Improved power for characterizing longitudinal amyloid-beta PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region. J Nucl Med. 2015;56(4):560\u20136.","journal-title":"J Nucl Med"},{"issue":"3","key":"2098_CR39","doi-asserted-by":"publisher","first-page":"fcac150","DOI":"10.1093\/braincomms\/fcac150","volume":"4","author":"L Lorenzini","year":"2022","unstructured":"Lorenzini L, et al. Regional associations of white matter hyperintensities and early cortical amyloid pathology. Brain Commun. 2022;4(3):fcac150.","journal-title":"Brain Commun"},{"issue":"10","key":"2098_CR40","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1212\/WNL.0b013e3181d3e3e9","volume":"74","author":"SM Resnick","year":"2010","unstructured":"Resnick SM, et al. Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11\u00a0C]PiB. Neurology. 2010;74(10):807\u201315.","journal-title":"Neurology"},{"issue":"1","key":"2098_CR41","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13195-019-0547-3","volume":"12","author":"O Grau-Rivera","year":"2020","unstructured":"Grau-Rivera O, et al. Association between insomnia and cognitive performance, gray matter volume, and white matter microstructure in cognitively unimpaired adults. Alzheimers Res Ther. 2020;12(1):4.","journal-title":"Alzheimers Res Ther"},{"key":"2098_CR42","doi-asserted-by":"crossref","unstructured":"Dean DC 3, et al. Association of amyloid pathology with myelin alteration in preclinical Alzheimer disease. JAMA Neurol. 2017;74(1):41\u20139.","DOI":"10.1001\/jamaneurol.2016.3232"},{"issue":"9","key":"2098_CR43","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41591-022-01925-w","volume":"28","author":"M Mila-Aloma","year":"2022","unstructured":"Mila-Aloma M, et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-beta pathology in preclinical Alzheimer\u2019s disease. Nat Med. 2022;28(9):1797\u2013801.","journal-title":"Nat Med"},{"issue":"1","key":"2098_CR44","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/s41467-017-01150-x","volume":"8","author":"S Palmqvist","year":"2017","unstructured":"Palmqvist S, et al. Earliest accumulation of beta-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat Commun. 2017;8(1):1214.","journal-title":"Nat Commun"},{"issue":"2","key":"2098_CR45","doi-asserted-by":"publisher","first-page":"100037","DOI":"10.1016\/j.tjpad.2024.100037","volume":"12","author":"HY Hu","year":"2025","unstructured":"Hu HY, et al. Microstructural white matter injury contributes to cognitive decline: Besides amyloid and tau. J Prev Alzheimers Dis. 2025;12(2):100037.","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"2098_CR46","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388(1):9\u201321.","journal-title":"N Engl J Med"},{"key":"2098_CR47","unstructured":"Li LL et al. Safety and short-term outcomes of lecanemab for Alzheimer\u2019s disease in China: a multicentre study. Brain. 2025 Nov 11:awaf427. Online ahead of print."},{"key":"2098_CR48","doi-asserted-by":"publisher","first-page":"106631","DOI":"10.1016\/j.phrs.2022.106631","volume":"187","author":"BP Imbimbo","year":"2023","unstructured":"Imbimbo BP, et al. Role of monomeric amyloid-beta in cognitive performance in Alzheimer\u2019s disease: insights from clinical trials with secretase inhibitors and monoclonal antibodies. Pharmacol Res. 2023;187:106631.","journal-title":"Pharmacol Res"},{"issue":"1","key":"2098_CR49","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","volume":"13","author":"CJ Swanson","year":"2021","unstructured":"Swanson CJ, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-abeta protofibril antibody. Alzheimers Res Ther. 2021;13(1):80.","journal-title":"Alzheimers Res Ther"},{"key":"2098_CR50","doi-asserted-by":"publisher","first-page":"105046","DOI":"10.1016\/j.ebiom.2024.105046","volume":"102","author":"J Therriault","year":"2024","unstructured":"Therriault J, et al. Comparison of two plasma p-tau217 assays to detect and monitor Alzheimer\u2019s pathology. EBioMedicine. 2024;102:105046.","journal-title":"EBioMedicine"},{"issue":"6","key":"2098_CR51","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/s41591-021-01348-z","volume":"27","author":"S Palmqvist","year":"2021","unstructured":"Palmqvist S, et al. Prediction of future Alzheimer\u2019s disease dementia using plasma phospho-tau combined with other accessible measures. Nat Med. 2021;27(6):1034\u201342.","journal-title":"Nat Med"},{"issue":"1","key":"2098_CR52","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/brain\/awaa399","volume":"144","author":"A Moscoso","year":"2021","unstructured":"Moscoso A, et al. Time course of phosphorylated-tau181 in blood across the Alzheimer\u2019s disease spectrum. Brain. 2021;144(1):325\u201339.","journal-title":"Brain"},{"key":"2098_CR53","doi-asserted-by":"crossref","unstructured":"Bright A, et al. Emerging connections between myelin and Alzheimer\u2019s disease. Nat Cell Biol. 2025;27(7):1049\u201351.","DOI":"10.1038\/s41556-025-01701-1"},{"issue":"1","key":"2098_CR54","doi-asserted-by":"publisher","first-page":"e213769","DOI":"10.1212\/WNL.0000000000213769","volume":"105","author":"J Selma-Gonzalez","year":"2025","unstructured":"Selma-Gonzalez J, et al. Association of plasma phosphorylated tau 217 with clinical deterioration across Alzheimer disease stages. Neurology. 2025;105(1):e213769.","journal-title":"Neurology"},{"key":"2098_CR55","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.neuroimage.2017.02.051","volume":"150","author":"SN Lockhart","year":"2017","unstructured":"Lockhart SN, et al. Amyloid and tau PET demonstrate region-specific associations in normal older people. NeuroImage. 2017;150:191\u20139.","journal-title":"NeuroImage"},{"issue":"5","key":"2098_CR56","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.neuron.2016.01.028","volume":"89","author":"M Scholl","year":"2016","unstructured":"Scholl M, et al. PET Imaging of tau deposition in the aging human brain. Neuron. 2016;89(5):971\u201382.","journal-title":"Neuron"},{"issue":"7","key":"2098_CR57","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1001\/jamaneurol.2019.0765","volume":"76","author":"N Mattsson","year":"2019","unstructured":"Mattsson N, et al. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2019;76(7):791\u20139.","journal-title":"JAMA Neurol"},{"issue":"11","key":"2098_CR58","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/S1474-4422(18)30318-1","volume":"17","author":"MK Rasmussen","year":"2018","unstructured":"Rasmussen MK, Mestre H, Nedergaard M. The glymphatic pathway in neurological disorders. Lancet Neurol. 2018;17(11):1016\u201324.","journal-title":"Lancet Neurol"},{"issue":"2","key":"2098_CR59","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-018-0297-y","volume":"25","author":"DA Nation","year":"2019","unstructured":"Nation DA, et al. Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med. 2019;25(2):270\u20136.","journal-title":"Nat Med"},{"issue":"5","key":"2098_CR60","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1002\/alz.13789","volume":"20","author":"SY Huang","year":"2024","unstructured":"Huang SY, et al. Glymphatic system dysfunction predicts amyloid deposition, neurodegeneration, and clinical progression in Alzheimer\u2019s disease. Alzheimers Dement. 2024;20(5):3251\u201369.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2098_CR61","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13195-025-01707-9","volume":"17","author":"PM Schirge","year":"2025","unstructured":"Schirge PM, et al. Perivascular space and white matter hyperintensities in Alzheimer\u2019s disease: associations with disease progression and cognitive function. Alzheimers Res Ther. 2025;17(1):62.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"2098_CR62","doi-asserted-by":"publisher","first-page":"6635","DOI":"10.1038\/s41467-022-34129-4","volume":"13","author":"A Pichet Binette","year":"2022","unstructured":"Pichet Binette A, et al. Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer\u2019s disease. Nat Commun. 2022;13(1):6635.","journal-title":"Nat Commun"},{"issue":"1","key":"2098_CR63","doi-asserted-by":"publisher","first-page":"4749","DOI":"10.1038\/s41598-019-41363-2","volume":"9","author":"F Ji","year":"2019","unstructured":"Ji F, et al. White matter microstructural abnormalities and default network degeneration are associated with early memory deficit in Alzheimer\u2019s disease continuum. Sci Rep. 2019;9(1):4749.","journal-title":"Sci Rep"},{"issue":"6","key":"2098_CR64","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1177\/0271678X231152001","volume":"43","author":"J Ottoy","year":"2023","unstructured":"Ottoy J, et al. Amyloid-PET of the white matter: relationship to free water, fiber integrity, and cognition in patients with dementia and small vessel disease. J Cereb Blood Flow Metab. 2023;43(6):921\u201336.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"4","key":"2098_CR65","doi-asserted-by":"publisher","first-page":"fcad192","DOI":"10.1093\/braincomms\/fcad192","volume":"5","author":"E Mak","year":"2023","unstructured":"Mak E, et al. Longitudinal associations between beta-amyloid and cortical thickness in mild cognitive impairment. Brain Commun. 2023;5(4):fcad192.","journal-title":"Brain Commun"},{"issue":"8","key":"2098_CR66","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1001\/jamaneurol.2019.1424","volume":"76","author":"BJ Hanseeuw","year":"2019","unstructured":"Hanseeuw BJ, et al. Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study. JAMA Neurol. 2019;76(8):915\u201324.","journal-title":"JAMA Neurol"},{"issue":"10","key":"2098_CR67","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.2967\/jnumed.117.204271","volume":"59","author":"VJ Lowe","year":"2018","unstructured":"Lowe VJ, et al. White matter reference region in PET studies of (11)C-Pittsburgh compound B uptake: effects of age and amyloid-beta deposition. J Nucl Med. 2018;59(10):1583\u20139.","journal-title":"J Nucl Med"},{"key":"2098_CR68","doi-asserted-by":"publisher","first-page":"748198","DOI":"10.3389\/fnagi.2021.748198","volume":"13","author":"SJ Teipel","year":"2021","unstructured":"Teipel SJ, et al. Partial volume correction increases the sensitivity of 18F-Florbetapir-Positron emission tomography for the detection of early stage amyloidosis. Front Aging Neurosci. 2021;13:748198.","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"2098_CR69","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13195-022-01035-2","volume":"14","author":"HJ Kim","year":"2022","unstructured":"Kim HJ, et al. The impact of subthreshold levels of amyloid deposition on conversion to dementia in patients with amyloid-negative amnestic mild cognitive impairment. Alzheimers Res Ther. 2022;14(1):93.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"2098_CR70","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13195-024-01494-9","volume":"16","author":"L Quenon","year":"2024","unstructured":"Quenon L, et al. Amyloid-PET imaging predicts functional decline in clinically normal individuals. Alzheimers Res Ther. 2024;16(1):130.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"2098_CR71","doi-asserted-by":"publisher","first-page":"12310","DOI":"10.1038\/s41598-024-62806-5","volume":"14","author":"H Okazawa","year":"2024","unstructured":"Okazawa H, et al. PET\/MRI multimodality imaging to evaluate changes in glymphatic system function and biomarkers of Alzheimer\u2019s disease. Sci Rep. 2024;14(1):12310.","journal-title":"Sci Rep"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-026-02098-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02098-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02098-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:03:49Z","timestamp":1785801829000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13195-026-02098-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2098"],"URL":"https:\/\/doi.org\/10.1186\/s13195-026-02098-1","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"4 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. All procedures conformed to the tenets of the Helsinki Declaration and the study protocol was approved by the Huashan Hospital, Shanghai (reference: KY2021555; Huashan cohort), and the First Hospital of Jilin University, Changchun (reference: 24k225-001; JLU-FH cohort).Written informed consent was obtained from all individual participants included in the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors affirm that all participants (or their legal guardians) provided informed consent for the publication of their anonymized data. No individually identifiable images or information are included in this manuscript.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"179"}}